Endometriosis is an estrogen-dependent condition and is characterized by the presence of ectopic endometrial tissue. The pathogenesis of this condition remains an enigma. Endometriosis has well known associations with menopause both in terms of secondary outcomes from medical and surgical therapy in premenopausal women, as well as a natural occurrence/recurrence of the disease in women going through menopause naturally. This review article aims to discuss the current day modalities of management of endometriosis with their pros and cons especially in the context of menopause and cancer.
RedwineDB. Was Sampson wrong?Fertil Steril2002;78:686–93
2.
GuoSW. The best-fit model for endometriosis. Fertil Steril2003;80:232–3
3.
MayK, BeckerCM. Endometriosis and angiogenesis. Minerva Ginecol2008;60:245–54
4.
Bruner-TranKL, Webster-ClairD, OsteenKG. Experimental endometriosis: the nude mouse as a xenographic host. Ann N Y Acad Sci2002;955:328–39
5.
KitawakiJ, KadoN, IshiharaH, KoshibaH, KitaokaY, HonjoH. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol2002;83:149–55
6.
HelouryY, GuiberteauV, SagotP, PlattnerV, BaronM, RogezJM. Laparoscopy in adnexal pathology in the child: a study of 28 cases. Eur J Pediatr Surg1993;3:75–8
7.
HantonEM, MalkasianGDJr, DockertyMB, PrattJH. Endometriosis associated with complete or partial obstruction of menstrual egress. Report of 7 cases. Obstet Gynecol1966;28:626–9
8.
ChatmanDL, WardAB. Endometriosis in adolescents. J Reprod Med1982;27:156–60
9.
SanfilippoJS, WakimNG, SchiklerKN, YussmanMA. Endometriosis in association with uterine anomaly. Am J Obstet Gynecol1986;154:39–43
10.
Rosa-e-SilvaJC, CarvalhoBR, BarbosaHF, Endometriosis in postmenopausal women without previous hormonal therapy: report of three cases. Climacteric2008;11:525–8
AlifanoM, JablonskiC, KadiriH, Catamenial and noncatamenial, endometriosis-related or nonendometriosis-related pneumothorax referred for surgery. Am J Respir Crit Care Med2007;176:1048–53
MahmoodTA, TempletonA. Prevalence and genesis of endometriosis. Hum Reprod1991;6:544–9
19.
Prevalence and anatomical distribution of endometriosis in women with selected gynaecological conditions: results from a multicentric Italian study. Gruppo italiano per lo studio dell'endometriosi. Hum Reprod1994;9:1158–62
20.
MoenMH, ScheiB. Epidemiology of endometriosis in a Norwegian county. Acta Obstet Gynecol Scand1997;76:559–62
21.
EskenaziB, WarnerML. Epidemiology of endometriosis. Obstet Gynecol Clin N Am1997;24:235–58
22.
AjossaS, MaisV, GuerrieroS, The prevalence of endometriosis in premenopausal women undergoing gynecological surgery. Clin Exp Obstet Gynecol1994;21:195–7
23.
WallerKG, LindsayP, CurtisP, ShawRW. The prevalence of endometriosis in women with infertile partners. Eur J Obstet Gynecol Reprod Biol1993;48:135–9
24.
BerubeS, MarcouxS, MaheuxR. Characteristics related to the prevalence of minimal or mild endometriosis in infertile women. Canadian Collaborative Group on Endometriosis. Epidemiology1998;9:504–10
25.
DowsettM. Drug and hormone interactions of aromatase inhibitors. Endocr Relat Cancer1999;6:181–5
26.
SareGM, GrayLJ, BathPM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J2008;29:2031–41
27.
NilasL, ChristiansenC. Bone mass and its relationship to age and the menopause. J Clin Endocrinol Metab1987;65:697–702
28.
NilasL, ChristiansenC. Rates of bone loss in normal women: evidence of accelerated trabecular bone loss after the menopause. Eur J Clin Invest1988;18:529–34
29.
ChristiansenC. Prevention and treatment of osteoporosis with hormone replacement therapy. Int J Fertil Menopausal Stud1993;38(Suppl. 1):45–54
30.
CundyT, EvansM, RobertsH, WattieD, AmesR, ReidIR. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ1991;303:13–6
31.
CundyT, ReidIR. Bone loss and depot medroxyprogesterone. Am J Obstet Gynecol1997;176:1116–7
32.
SchlaffWD, CarsonSA, LucianoA, RossD, BergqvistA. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril2006;85:314–25
33.
SelakV, FarquharC, PrenticeA, SinglaA. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev2007;(4):CD000068
MitwallyMF, CasperRF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril2001;75:305–9
36.
SantenRJ, HarveyHA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer1999;6:75–92
37.
SoysalS, SoysalME, OzerS, GulN, GezginT. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod2004;19:160–7
38.
HaradaT, MomoedaM, TaketaniY, Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis – a randomized, double-blind, multicenter, controlled trial. Fertil Steril2009;91:675–81
BedaiwyMA, CasperRF. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain. Fertil Steril2006;86:220–2
41.
MacLennanAH, BroadbentJL, LesterS, MooreV. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev2004;(4):CD002978
42.
SagsveenM, FarmerJE, PrenticeA, BreezeA. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev2003;(4):CD001297
43.
CrosignaniPG, De CeccoL, GastaldiA, Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. Hum Reprod1996;11:2732–5
44.
EdmondsDK. Add-back therapy in the treatment of endometriosis: the European experience. Br J Obstet Gynaecol1996;103(Suppl. 14):10–3
45.
WheelerJM, MalinakLR. Recurrent endometriosis: incidence, management, and prognosis. Am J Obstet Gynecol1983;146:247–53
46.
NamnoumAB, HickmanTN, GoodmanSB, GehlbachDL, RockJA. Incidence of symptom recurrence after hysterectomy for endometriosis. Fertil Steril1995;64:898–902
RanaN, RotmanC, HassonHM, RedwineDB, DmowskiWP. Ovarian remnant syndrome after laparoscopic hysterectomy and bilateral salpingo-oophorectomy for severe pelvic endometriosis. J Am Assoc Gynecol Laparosc1996;3:423–6
50.
DoverRW, ChenJ, TorodeH. Oophorectomy at the time of surgery for moderate endometriosis: a survey of Australian gynaecologists. Aust N Z J Obstet Gynaecol2000;40:455–8
51.
RedwineDB. Endometriosis persisting after castration: clinical characteristics and results of surgical management. Obstet Gynecol1994;83:405–13
NikolovA, DimitrovA, IlievD, GenovN. Endometriosis during postmenopausal period – probable causes for its origin and development. Akush Ginekol (Sofiia)2004;43:50–3
CumiskeyJ, WhyteP, KelehanP, GibbonsD. A detailed morphologic and immunohistochemical comparison of pre- and postmenopausal endometriosis. J Clin Pathol2008;61:455–9
56.
GohJT, HallBA. Postmenopausal endometrioma and hormonal replacement therapy. Aust N Z J Obstet Gynaecol1992;32:384–5
57.
RattanachaiyanontM, TanmahasamutP, AngsuwatthanaS, TechatraisakK, InthawiwatS, LeerasiriP. Hormonal replacement therapy in surgical menopause with underlying endometriosis. J Med Assoc Thai2003;86:702–7
58.
DowsettM, HarrisAL, SmithIE, JeffcoateSL. Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer. Br J Cancer1984;50:357–61
59.
Le BouedecG, KauffmannP, PingeonJM, de LatourM, LemesleP, DauplatJ. Post-menopausal endometriosis developed during tamoxifen treatment. Rev Fr Gynecol Obstet1991;86:407–10
SolimanNF, HillardTC. Hormone replacement therapy in women with past history of endometriosis. Climacteric2006;9:325–35
64.
MatorrasR, ElorriagaMA, PijoanJI, RamonO, Rodriguez-EscuderoFJ. Recurrence of endometriosis in women with bilateral adnexectomy (with or without total hysterectomy) who received hormone replacement therapy. Fertil Steril2002;77:303–8
65.
FedeleL, BianchiS, RaffaelliR, ZanconatoG. Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. Maturitas1999;32:189–93
66.
NomuraS, SuganumaT, SuzukiT, Endometrioid adenocarcinoma arising from endometriosis during 2 years of estrogen replacement therapy after total hysterectomy and bilateral salpingo-oophorectomy. Acta Obstet Gynecol Scand2006;85:1019–21
67.
Al TalibA, GilbertL, ArseneauJ. Endometrioid adenocarcinoma 13 years after total abdominal hysterectomy and bilateral salpingo-oophorectomy. Saudi Med J2008;29:1044–7
68.
KobayashiH, SumimotoK, KitanakaT, Ovarian endometrioma – risks factors of ovarian cancer development. Eur J Obstet Gynecol Reprod Biol2008;138:187–93
69.
Van GorpT, AmantF, NevenP, VergoteI, MoermanP. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol2004;18:349–71
70.
OlsonJE, CerhanJR, JanneyCA, AndersonKE, VachonCM, SellersTA. Postmenopausal cancer risk after self-reported endometriosis diagnosis in the Iowa Women's Health Study. Cancer2002;94:1612–8
71.
WuX, HawseJR, SubramaniamM, GoetzMP, IngleJN, SpelsbergTC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res2009;69:1722–7
72.
BeseT, KosebayD, DemirkiranF, ArvasM, BeseN, MandelN. Ultrasonographic appearance of endometrium in postmenopausal breast cancer patients receiving tamoxifen. Eur J Obstet Gynecol Reprod Biol1996;67:157–62
73.
CohenI, AltarasMM, LewS, TepperR, BeythY, Ben BaruchG. Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature. Gynecol Oncol1994;55(part 1):443–7
